[go: up one dir, main page]

AU2001261324A1 - Psoriasis treatment - Google Patents

Psoriasis treatment

Info

Publication number
AU2001261324A1
AU2001261324A1 AU2001261324A AU6132401A AU2001261324A1 AU 2001261324 A1 AU2001261324 A1 AU 2001261324A1 AU 2001261324 A AU2001261324 A AU 2001261324A AU 6132401 A AU6132401 A AU 6132401A AU 2001261324 A1 AU2001261324 A1 AU 2001261324A1
Authority
AU
Australia
Prior art keywords
psoriasis treatment
psoriasis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001261324A
Inventor
Eugene M. Farber
Siba P. Raychaudhuri
Smriti K. Raychaudhuri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PSORIASIS RESEARCH INSTITUTE
Original Assignee
PSORIASIS RES INST
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PSORIASIS RES INST filed Critical PSORIASIS RES INST
Publication of AU2001261324A1 publication Critical patent/AU2001261324A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Environmental Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001261324A 2000-05-08 2001-05-08 Psoriasis treatment Abandoned AU2001261324A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56657400A 2000-05-08 2000-05-08
US09566574 2000-05-08
PCT/US2001/014988 WO2001085151A2 (en) 2000-05-08 2001-05-08 Chimeric animal model and treatment of psoriasis

Publications (1)

Publication Number Publication Date
AU2001261324A1 true AU2001261324A1 (en) 2001-11-20

Family

ID=24263461

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001261324A Abandoned AU2001261324A1 (en) 2000-05-08 2001-05-08 Psoriasis treatment

Country Status (2)

Country Link
AU (1) AU2001261324A1 (en)
WO (1) WO2001085151A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2524883C (en) 2003-05-16 2014-07-22 Universite Laval Potassium-chloride cotransporter kcc2 modulation for treatment of pain
WO2005014003A1 (en) * 2003-07-23 2005-02-17 Creabilis Therapeutics S.R.L. Topical use of tyrosine kinase inhibitors of microbial origin to prevent and treat skin disorders characterised by excessive cell proliferation
EP1750772A4 (en) 2004-05-14 2009-09-09 Univ Laval MODULATION OF PHOSPHOLIPASE C GAMMA AND ITS USES FOR THE MANAGEMENT OF PAIN AND NOCICEPTION
AU2006284096B2 (en) * 2005-08-25 2012-03-29 Avro Life Sciences, Inc. Polymer conjugates of K-252a and derivatives thereof
ES2352929B1 (en) * 2009-08-14 2012-01-26 Centro De Investigaciones Energeticas. Medioamb Ientales Y Tecnologicas (Ciemat) HUMANIZED PSORIASIS MODEL
FR3045385B1 (en) 2015-12-22 2019-12-20 Jean-Noel Thorel COSMETIC COMPOSITION COMPRISING NERVE GROWTH FACTOR EXPRESSION INHIBITORS FOR THE TREATMENT OF PSORIASIS, ATOPIC DERMATITIS AND PRURITUS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945576A (en) * 1996-04-05 1999-08-31 Brigham & Women's Hospital, Inc. Mouse model of psoriasis
EP0912184B1 (en) * 1996-06-25 2002-09-25 Cephalon, Inc. Use of k-252a derivative for the treatment of peripheral or central nerve disorders, and cytokine overproduction
WO1998044908A1 (en) * 1997-04-07 1998-10-15 The Board Of Trustees Of The Leland Stanford Junior University Method of regulating epithelial growth
US6013646A (en) * 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
IT1302264B1 (en) * 1998-09-24 2000-09-05 Innovet Italia Srl DERIVATIVES WITH N-ACYL VANILLYAMIDE STRUCTURE ABLE TO ACTIVATE PERIPHERAL IRECEPTORS OF CANNABINOIDS

Also Published As

Publication number Publication date
WO2001085151A2 (en) 2001-11-15
WO2001085151A3 (en) 2002-05-23

Similar Documents

Publication Publication Date Title
AU2002223827A1 (en) Well treatment
AU2001260513A1 (en) Microcapsule well treatment
AU2002215125A1 (en) Well treatment method
AU2002222853A1 (en) Therapeutic compounds
AU2001239858A1 (en) Wastewater treatment process
AU5089400A (en) Arthritis treatment
AU5547000A (en) Novel treatment
AU2002324201A1 (en) Waste treatment
AU2001226910A1 (en) Electrolytic treatment
AU2002319286A1 (en) Skin treatment
AU2001257325A1 (en) Cancer treatment
AU4556800A (en) Novel treatment
AU2001236929A1 (en) Surface treatment
AU2002227925A1 (en) Human beta-defensin-3
AU2002335667A1 (en) Modified reoviral therapy
AU2001261324A1 (en) Psoriasis treatment
AU2001294183A1 (en) Waste treatment equipment
AU2001289127A1 (en) Tumor treatment
AU2001292897A1 (en) Novel therapy
AU2001253560A1 (en) Methods of treatment
AU2001257168A1 (en) Cancer treatment
AU2001271537A1 (en) Cough treatment
AUPR814901A0 (en) Water treatment
HK1052634A (en) Treatment of psoriasis
AU3579101A (en) Waste treatment